MAM
LCTX icon

Meeder Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Meeder Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5
Closed – – 2430
2021
Q4 		$0 Buy
+5
New +$12 ﹤0.01% 1794
2018
Q4 		– Sell
-2,029
Closed -$4K – 1757
2018
Q3 		$4K Buy
+2,029
New +$4.26K ﹤0.01% 1368
2018
Q1 		– Sell
-162
Closed – – 1649
2017
Q4 		$0 Buy
+162
New +$354 ﹤0.01% 1728
2017
Q3 		– Sell
-253
Closed -$1K – 1699
2017
Q2 		$1K Sell
253
-749
-75% -$2.09K ﹤0.01% 1526
2017
Q1 		$3K Buy
+1,002
New +$2.85K ﹤0.01% 1264

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return